The metabolism of human IgE was studied in normals, severe atopics, and patients with the hyperimmunoglobulin E-recurrent infection (HIE; Job's) syndrome to determine whether IgE metabolism is altered in patients with marked elevation of serum IgE. Purified polyclonal '"I-IgE was administered intravenously and serial plasma and urine samples were obtained. After analysis, the metabolic data support previously published evidence that IgE (at concentrations found in normal individuals) is catabolized at a higher fractional rate than other immunoglobulins and is catabolized by both an intravascular and an extravascular pathway. In addition, the data show that the fractional catabolic rate for IgE is significantly less for the atopic patients (mean±SEM = 0.20±0.01) and for the HIE patients (0.15±0.02) than for the normal volunteers (0.52±0.06; P < 0.01) and is inversely related (r = -0.851; P < 0.001) to the serum IgE concentration. These findings have specific importance in showing that decreased fractional catabolic rate contributes substantially to elevation of IgE in atopic and HIE patients. In addition, the findings have general significance in that they lead to a unifying hypothesis of immunoglobulin catabolism.
Introduction
Immunoglobulin E has the unique biologic property ofmediating antigen-dependent immediate hypersensitivity reactions via binding to high-affinity Fc-epsilon receptors on mast cells and basophils (1) . Previous studies of IgE metabolism (2-6) established that IgE is more slowly synthesized and more rapidly catabolized than other immunoglobulin classes (7) . It is cleared from the plasma at a rate -10 times that of IgG, 4 times that of IgM, and IgA and 2 times that of IgD. Other conclusions of earlier metabolic studies were that IgE, unlike IgG, IgA, or IgM is subject to at least two catabolic pathways (6) and that at very high IgE concentrations (in patients with IgE myeloma), IgE catabolism is greatly reduced. In the following study we have attempted to explore further the metabolism of IgE by examining IgE turnover in patients with a wide spectrum of IgE concentrations, including patients with elevated IgE levels associated with severe atopic disease and patients with the hyperimmu-noglobulin E-recurrent infection (HIE; Job's) syndrome (8) .
Other important aspects of the current investigation are the use of polyclonal IgE isolated from a patient with HIE rather than the use of the myeloma proteins previously studied and the application of advanced computer analysis with the SAAM-27 program (9) for data analysis.
The data obtained support earlier findings (6) that IgE is catabolized at a higher fractional rate than are other immunoglobulins and is catabolized by both an extravascular and intravascular pathway. A new finding is that IgE is cleared from the plasma more slowly (decreased fractional catabolic rate [FCR]) by both groups of patients with markedly elevated IgE concentrations and that (for all subjects) the rate of clearance is inversely related to the serum IgE level. In addition, the fractional clearance of IgE in patients with markedly elevated IgE is similar to that seen for other immunoglobulins under limiting conditions. Finally, although patients with markedly elevated IgE have a substantial increase in the mass ofextravascular IgE, the proportion of their total IgE that is in the extravascular space is decreased compared with normals and is inversely related to the serum IgE concentration. These findings, in the context of previous studies have led us to a unifying hypothesis of immunoglobulin catabolism.
Methods
Patients. Individuals included in this study were as follows: (a) Five patients with HIE (IgE, geometric mean X/. relative SEM = 34,500 ng/ml X/-. 1.6) were reported previously by Donabedian and Gallin (8) as patients 3, 7, 10, 12, 13, and 16 . At the time of study, three of the HIE patients were in relatively good health, whereas two were recovering from serious Staphylococcus aureus infections; all were clinically stable.
(b) Five patients had severe atopic disease (IgE, geometric mean X/. relative SEM = 1 1,880 ng/ml X/±. 3.6). This group included two patients with severe (10) atopic dermatitis (using topical steroids), one patient with allergic bronchopulmonary aspergillosis (prednisone 25 mg QOD), and one patient with allergic asthma (prednisone 17.5 mg QOD). At the time of study, all of the atopic patients were in generally good health (the two patients taking oral steroids were studied 48 h after a dose of prednisone with the subsequent dose delayed until 4 h after injection of the tracer). (c) Five normal volunteers (IgE, geometric mean X/+. relative SEM = 70 ng/ml x/±. 2.1) were also studied. Three had negative histories of allergic disease, two had a history of mild seasonal rhinitis, and none had atopic dermatitis. None (15) and addressed via the CONSAM communications software (16) utilizing a DEC 11/780 computer (Digital Equipment Corp., Maynard, MA) (17) (18) (19) . This analysis allows the estimation of metabolic parameters using alternative compartmental models. Fitting is carried out by iterative adjustment of parameters so as to minimize least square differences between observed and calculated values. Both the plasma die-away curve and the urine excretion curves are utilized by the SAAM program to generate the best fit for all the data. Using this program, one can estimate (17, 18 ) for a chosen model, the FCR, the absolute catabolic rate, the synthetic rate, the size of each compartment, and the intercompartmental rate constants.
Statistical analysis. All summary data are expressed as either the arithmetic mean±SEM or the geometric mean X/-the relative SEM. Data were evaluated by the use of a two-tailed Student's t test or by Spearman rank-correlation coefficients.
Results
IgE was purified from a patient with the HIE syndrome, iodinated, and then used in the metabolic studies to be described. As mentioned in Methods, 65% of the counts bound to cultured human basophils (Ishizaka, T., personal communication) and 5% were composed of free iodine. To explore further the integrity of the 125ImgE used in these studies, the distribution of 1251I was analyzed on HIPLC before (Fig. 2 A) and, by chromatography of whole serum, at various times after injection (Fig. 2 , B-D). As can be seen, the '25I-IgE was homogeneous before injection and circulated in an unaltered state after injection. This was the case in three of three normals and three of four patients with elevated IgE (data not shown). However, in one of three HIE patients examined, 25% of the radioactive material eluted in the void volume. This may represent IgE immune complexes.
The '25I-IgE was then utilized in metabolic studies. The primary data obtained were used to generate a composite plasma and a composite cumulative urine excretion curve for each of zw -c Figure 2 . HPLC of 1251. the groups studied. As can be seen in Fig. 3 , the atopics and the HIE patients clear the radioactivity more slowly from the plasma (Fig. 3 A) and excrete it more slowly into the urine (Fig. 3 B) . Thus, the percentage of the injected dose remaining at day 6 in the plasma of both the HIE patients and the atopic patients is significantly less than that remaining in the normal volunteers (P < 0.05 for atopic; P < 0.001 for HIE). In a complementary fashion, the cumulative excretion of radioactivity at day 6 is greater in the normal volunteers than for the patients with HIE (P < 0.01).
Utilizing the SAAM-27 program, we evaluated several compartmental models for their capacity to fit the primary metabolic data. Of the models studied, only the model shown in Fig. 4 gave a good fit for the data from all three patient groups. Omission of any component resulted in a larger sum of square difference between the observed and calculated values.
In this model, pools I and 2 represent IgE-bound radioactivity in the plasma. These pools are different in that pool 1 contains (in the initial conditions) the fraction of '25IIgE that could bind human basophils in vitro ("native" IgE) whereas the fraction of 125I1IgE that could not bind to these cells ("denatured" IgE) is placed in pool 2. The material in pool 1 can be catabolized by a direct (intravascular) pathway into the iodide pool (pool 3), can exchange with an extravascular exchangeable compartment (pool 4), or can be catabolized irreversibly via an indirect (extravascular) pathway (pool 5). Specific information concerning the extravascular compartments 4 and 5 is limited in that samples were obtained only from the plasma and the urine. Ra- dioactivity in pool 1 leaves the plasma and can either return (via compartment 4) or is irreversibly lost from the plasma. The latter component appears either as radioactivity in the urine (compartment 6) quickly via compartment 3 (the iodide pool) or after a delay (via compartment 5 and then 3). It is indeterminant whether material enters compartment 5 from compartment 1, from compartment 4, or from both; thus, dashed lines are drawn for these pathways in Fig. 4 . It is possible that compartments 4 and 5 may not, in fact, be separate. The material in pool 2 ("nonbindable" or "denatured" IgE) can only circulate in the plasma and be degraded directly via an intravascular process that is faster than, and independent of, the direct (intravascular) catabolic pathway affecting the "bindable" IgE. Thus, the nonbindable 1251IIgE is removed from further consideration.
Based on the data of IgE binding (see Methods), we chose initial conditions such that 65% of the tracer IgE is placed in pool 1 and 30% of the tracer is in pool 2. Compartment 3 represents free iodide or iodinated tyrosine (freely exchangeable between the intravascular and extravascular spaces) and initially contains the remaining 5% of the tracer found in our final preparations.
Representative computer plots of observed and calculated data from a single normal volunteer are shown in Fig. 5 . Fig. 3 B) . As can be seen, there is a rise 1766 Dreskin, Goldsmith, Strober, Zech, and Gallin in the observed fractional 1251 excretion at day 3 (Fig. 5 B) . This rise is a consistent finding in virtually all studies and is the feature ofthe metabolic data that mandated the need for a delay catabolic pathway through pool 5.
IgE metabolic data for each subject are listed in Tables I-III. Table I lists the serum IgE, the intravascular IgE, the FCR, and the IgE synthetic rate. The intravascular IgE is the product of the serum IgE concentration and the plasma volume. The FCR represents the sum of the rate constants governing the movement of label irreversibly from compartment 1 as defined by the expression:
where X31 and X51 are rate constants for the movement of label from pool 1 to pools 3 and 5, respectively. In the steady state, the synthetic rate is equal to the absolute catabolic rate and thus was obtained by multiplying the intravascular IgE concentration by the FCR. It can be seen that the FCR in normals (0.52±0.06) is significantly larger than for atopic patients (0.20±0.01; P < 0.01) or for HIE patients (0.15±0.02; P < 0.001), whereas the difference between the FCRs for atopics and HIE patients is not statistically significant. In comparing individual FCRs with individual serum IgE concentrations, the FCR is inversely related (Spearman rank-correlation coefficient) to the serum IgE levels (r = -0.851; P < 0.001); this is shown graphically in Fig. 6 . Finally, the synthetic rate data reveal that, on the average, patients with markedly elevated IgE have a lower IgE synthetic rate (60% less for atopics; 71% less for HIE) than would be predicted on the basis of elevated serum IgE alone (given a constant FCR). Thus, for an individual patient (e.g. S.W.), the measured IgE synthetic rate can be as low as 15% of that predicted on the basis of the FCR found in normals. Table II lists the total body IgE, the intravascular IgE, the extravascular IgE, and the percentage of the total IgE that is extravascular. These values are derived from measurement of the mass of IgE in pool 1 and determination of the steady state rate constants. The latter (X41, X14, X51, X35) are derived from the compartmental model (Fig. 4) . The following formulas were used to determine the distribution of IgE: 
As can be seen in Table II 
As shown in the last column of Table III ). This finding may be related to the observation that this is the patient who had evidence of immune complexes on HPLC (see above).
jo-Discussion I&Ĩ gE (ng/mI) Figure 7 . Extravascular IgE as a percentage of the total body IgE is shown as a function of serum IgE levels in the 12 subjects for whom there was adequate data to calculate this parameter. Spearman rankcorrelation coefficient, r = -0.8 10; P < 0.01). A line is drawn for interpretative purposes only. Table II , the absolute amount of extravascular IgE increases as the serum IgE increases (r = 0.991; P < 0.001). However, it is important to note that the proportion of the total IgE that is extravascular decreases as the serum IgE concentration increases (r = -0.810; P < 0.01) (Table II and Fig. 6 ), suggesting that the rise in serum IgE is greater than the increase in available binding sites. A related interesting observation is that the proportion of the IgE that is catabolized by the extravascular pathway is inversely related to the serum IgE concentration and is directly relatedto the proportion of IgE that is extravascular (see Table III (Table II) is compatible with published observations that patients with elevated IgE have increased numbers ofIgE receptors on circulating basophils (26) and lymphocytes (27, 28) . In addition, up-regulation of IgE receptors (after exposure to high concentrations of IgE) has been observed in vitro for rat basophil leukemia cells (29) and for mouse macrophages and lymphocytes (30) , suggesting that this may be a general finding for cells bearing IgE receptors.
In spite of the above arguments, at least two objections can be raised to the idea that the high-affinity IgE receptor of the mast cell is an important extravascular catabolic site. First, there are several studies indicating that cutaneously injected IgE turns over very slowly in comparison to the turnover of IgE moving through the extravascular catabolic pathway as described in this study. Thus, the calculated t4, of skin-sensitizing activity after administration of reagnic serum (31) and the to of '3'I-IgE injected subcutaneously (32) (33) . This discrepancy is partially mitigated by the fact that in yet another study (34), the t½ of subcutaneously injected reaginic serum was estimated to be 4.2-4.9 d. In addition, it should be kept in mind that while the disappearance of Prausnitz-Kustner reactivity and the catabolism of IgE are closely related, they are not the same phenomena. Finally, the connective tissue mast cell is only one of several types of tissue mast cells (35) and those in the skin probably represent a relatively minor proportion of the total body IgE high-affinity binding sites.
A second objection to the hypothesis that the high-affinity IgE receptor of the mast cell may mediate IgE catabolism is that monomeric IgE bound to the rat high-affinity IgE receptor of the basophilic leukemia cell is not catabolized (36, 37) . However, although this cell line resembles mucosal mast cells (35) , there are marked ultrastructural differences between the two cell types and there may also be differences in the manner in which these cells handle IgE monomers. In addition, it is not known whether other cell types with high-affinity receptors for IgE (e.g., bone marrow-derived mast cells, connective tissue mast cells, and basophils) can catabolize monomeric IgE. Finally, as mentioned above, there are other cells with low-affinity IgE receptors, specifically macrophages (30, 38) , lymphocytes (27, 28, 39) , and eosinophils (40) in which the issue of IgE catabolism has not been studied and thus remain as possible sites of catabolism.
In conclusion, evidence has been presented that supports 
